Friday, May 01, 2020 10:39:55 AM
The fundamental idea is to use computer modeling to discover a structure that will mimic the glycoprotien(s) on the surface of cells to which the virus will attach.
The next challenge is to find out how to make that molecule in quantity, repeatedly, and to required standards.
Another problem might be in the manufacture of a micelle of an effective kind, and the attachment of the ligand to those micelles, etc.
Then there could be two more fatal problems: 1) the viruses will not at all or sufficiently attach to the ligands, 2) if attached, the micelle will not merge itself with the envelope of the virus and destroy it.
Is there something wrong with any of these, other than that each is hard to do and would take a long time to get right, if ever?
If none of the above is the problem, as you see it, then what is?
Or perhaps you think that even if all the above is possible that Diwan is incapable of doing it, although someone else might succeed?
I'm genuinely interested in your answer.
The next challenge is to find out how to make that molecule in quantity, repeatedly, and to required standards.
Another problem might be in the manufacture of a micelle of an effective kind, and the attachment of the ligand to those micelles, etc.
Then there could be two more fatal problems: 1) the viruses will not at all or sufficiently attach to the ligands, 2) if attached, the micelle will not merge itself with the envelope of the virus and destroy it.
Is there something wrong with any of these, other than that each is hard to do and would take a long time to get right, if ever?
If none of the above is the problem, as you see it, then what is?
Or perhaps you think that even if all the above is possible that Diwan is incapable of doing it, although someone else might succeed?
I'm genuinely interested in your answer.
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
